Epstein Secrets

modest decline in the growth rate in recent years, healthcare continues to account for a very high portion of U.S. GDP. The Centers for Medicare and Medicaid (CMS) estimates healthcare spending in the United States will reach $5 trillion in 2022 and represent about 20 percent of GDP. Long term CMS expect

ners, and there is a potential for additional conflicts of interest between the Fund and such co-investors since they may have diverging interests. Long-Term Investment An investment in the Fund requires a long-term commitment. The Fund may choose to hold its investments for longer than the anticipated five (5)- to

oval process for generic biologics and granting exclusive marketing rights to original manufacturers for 12 years, (iv) increased drug rebates to the Medicaid program, and (v) disclosure requirements for financial relationships between various healthcare entities. Within the U.S., the pharmaceutical indust

cation of investment opportunities by the General Partner will not give rise to conflicts of interest between the investors of the respective funds. Long-Term Investment An investment in the Fund is a long-term commitment, and there is no assurance of any distribution to the Limited Partners prior to or upon liquidati

healthcare spending and its seemingly relentless growth are problematic for the US. Public spending on healthcare—primarily through the Medicare and Medicaid programs—is crowding out other state and national priorities, including education, social security, national defense, and deficit eduction. High he

the Fund's Partnership Agreement could be disruptive to the smooth operation of the Fund or otherwise frustrate the expectations of the Partners. Long-Term Investment An investment in the Fund is a long-term commitment and there is no assurance of any distribution to the Limited Partners. Limited Transferability